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Abstract
Angiogenesis is an important component of cancer growth, invasion and metastasis. Therefore, inhibition of angio-
genesis is an attractive strategy for treatment of cancer. We describe existing clinical trials of antiangiogenic agents
and the challenges facing the clinical development and optimal use of these agents for the treatment of breast
cancer. Currently, the most promising approach has been the use of bevacizumab, a humanized monoclonal anti-
body directed against the most potent pro-angiogenic factor, vascular endothelial growth factor (VEGF). Small
molecular inhibitors of VEGF tyrosine kinase activity, such as sorafenib, appear promising. While, the role of suniti-
nib and inhibitors of mammalian target of rapamycin (mTOR) in breast cancer has to be defined. Several unan-
swered questions remain, such as choice of drug(s), optimal duration of therapy and patient selection criteria.
Introduction
Angiogenesis is a pivotal component of cancer growth,
including invasion and metastasis. Tumours induce
blood vessel growth (angiogenesis) by secreting various
growth factors (for example, vascular endothelial growth
factor (VEGF)). Growth factors, such as basic fibroblast
growth factor and VEGF, can induce capillary growth
into the tumour, which allows tumour expansion. Thus,
angiogenesis is a necessary and required step for transi-
tion from a small harmless cluster of cells to a large
tumour and is also required for the spread of a tumour,
invasion and/or metastasis. The inhibition of angiogen-
esis is emerging as a new, attractive therapeutic approach
to control tumour progression [1]. At present, several
antiangiogenic therapies are in clinical trials testing their
promise in breast cancer. This review focusses on clinical
aspects of treatment of breast cancer with monoclonal
antibodies, and tyrosine kinase and mammalian target of
rapamycin (mTOR) inhibitors. In addition, new pivotal
angiogenic pathways, such as the Notch ligand Delta-like
4 pathway, are briefly reviewed.
Methods
The data were obtained by searching in the PubMed data-
base. The search terms used included ‘antiangiogenic ther-
apy’, ‘targeted therapy’ and ‘(metastatic) breast cancer’.I n
addition, specific drugs (for example, bevacizumab,
sunitinib, and temsirolimus) were included in the search.
Our primary focus was phase II and III trials, as only very
few phase III trials were identified. Full articles were
obtained and references were checked for additional infor-
mation when appropriate. Proceedings from conferences
of the American Society of Clinical Oncology (ASCO), the
American Association of Cancer Research (2005 to 2009),
and the San Antonio Breast Cancer Symposium (2005 to
2009) were searched for relevant abstracts. Data were
updated through July 2010.
Antiangiogenic therapy
In situ hybridization studies have demonstrated expres-
sion of VEGF mRNA in many human tumours, includ-
ing breast cancer. Thus, VEGF appears to be one of the
key players, and current antiangiogenic strategies have
therefore mainly aimed at blocking the action of VEGF.
Such inhibition can be achieved by direct targeting of
the ligand (VEGF) at the mRNA or protein level, direct
targeting of its receptors (VEGFR1, VEGFR2, and
neuro-pilin-1), or by blocking components of the down-
stream signaling pathway [2,3].
Inhibitors of VEGF: monoclonal antibodies
Bevacizumab in metastatic breast cancer
Bevacizumab (Avastin®; Genentech Inc., San Francisco,
CA, USA; Hoffmann-La Roche Ltd, Basel, Switzerland)
is a recombinant humanized monoclonal antibody that
binds VEGF and prevents it from binding to its recep-
tors [4]. A phase I/II study of bevacizumab monotherapy
in patients with previously treated metastatic breast
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© 2010 BioMed Central Ltdcancer (MBC) has shown a response rate (RR) of 7%
with a median duration of 5.5 months (range 2.3 to 13.7
months); at tumour assessment on day 154, 16% of the
patients had stable disease (SD) or an ongoing response
[5]. Clinical studies indicate that the anti-neoplastic
activity of bevacizumab as monotherapy is modest.
Table 1 summarises the results from phase II trials uti-
lizing bevacizumab in combination with chemotherapy,
many of which are still preliminary. In these studies,
bevacizumab was given as both first-line and later lines
of therapy but the results were not always reported
separately [6-18]. A first- and second-line phase II trial
of bevacizumab in combination with docetaxel demon-
strated a RR of 52% and median progression-free survi-
val (PFS) of 7.5 months [6]. Furthermore, results from a
phase II study of bevacizumab plus capecitabine as first-
line therapy revealed encouraging results with an 81%
clinical benefit rate (CBR; 6% complete response (CR),
33% partial response (PR) and 43% SD (duration not
reported)) [15]. In contrast, a phase II trial of pegylated
liposomal doxorubicin and bevacizumab had to be
stopped prematurely because of toxicity (including one
cardiac toxicity grade 4). The efficacy was modest with
an RR of 23% and a median PFS of 7.5 months [18].
Results of phase III trials comparing chemotherapy
regimens with and without bevacizumab are given in
Table 2. A phase III study involving 462 patients with
heavily pretreated MBC was rather disappointing. Add-
ing bevacizumab to capecitabine did not improve the
primary endpoint PFS (4.8 versus 4.2 months; hazard
ratio = 0.98; 95% confidence interval, 0.77 to 1.25) or
overall survival (OS; 15.1 versus 14.5 months), despite a
doubling in objective RR in the combination arm com-
pared with the capecitabine arm (20 versus 9%) [19].
This lack of benefit raises several questions about the
mechanisms of antiangiogenic therapy (see the Discus-
sion section).
A phase III trial (E2100) including 722 patients (90%
human epidermal growth factor receptor 2 (HER2)-
negative) randomised to first-line treatment with
paclitaxel or paclitaxel plus bevacizumab has been com-
pleted. Analysis revealed increased RR (21 versus 37%,
P < 0.001) and a doubling in median PFS (5.9 versus 11.8
months, P < 0.001) [20]. The OS, however, was similar in
the two groups (25.2 versus 26.7 months, P = 0.16). Data
on treatment administered after progression were not
collected in this trial, precluding an exploratory analysis
of the influence of subsequent therapy on OS.
More recently, results from a phase III trial (AVADO)
including 736 patients randomised to first-line treatment
with docetaxel plus placebo or docetaxel plus bevacizu-
mab (two doses) has been reported. Analysis revealed
Table 1 Phase II trials of bevacizumab in combination with chemotherapy in metastatic breast cancer
Reference Number of patients Therapy ORR (%) PFS
(months)
Ramaswamy et al. [6] 27 (78% HER2-negative) B + docetaxel 52 (1st + 2nd line) 8
Chan et al. [7] 43 (21 evaluable) B + docetaxel Approximately 40 (1st line) NR
Hurvitz et al. [8] 69 (67 evaluable; HER2-
negative)
B + docetaxel 48 (1st line) 8 (TTP)
Perez et al. [9] 45 (HER2-negative) B + docetaxel + capecitabine 49 (1st line) 11
69 (CBR)
Hoelzer et al. [10] 61 (57 evaluable) B + paclitaxel 42 (1st line) 15
58 (54 evaluable) B + paclitaxel + gemcitabine 48 20
Guardino et al. [11] 21 (17 evaluable) B + paclitaxel + gemcitabine 88 (CBR) NR
Rugo et al. [12] 46 B + ixabepilone (weekly) 50 (1st line) NR
45 B + ixabepione (q3w) 71 NR
32 B + paclitaxel 56 NR
Danso et al. [13] 49 (27 evaluable; HER2-
negative)
B + nab-paclitaxel 30 (1st line) 9
Conlin et al. [14] 72 B + nab-paclitaxel (three dosing
schedules)
42 (1st line) 9 (TTP)
54 42 6
76 42 8
Sledge et al. [15] 103 B + capecitabine 39 (1st line) NR
Traina et al. [16] 29 B + capecitabine 31 (various; 10 pts with SD >6
months)
NR
Dellapasqua et al. [17] 46 B + capecitabine + cyclophosphamide 48 (1st to 3rd line) 10 (TTP)
Rochlitz et al. [18] 41 B + pegylated liposomal doxorubicin 23 (1st line) 8
Studies with ≥15 evaluable patients are included. B, bevacizumab; CBR, clinical benefit rate; NR, not reported; ORR, overall response rate; PFS, progression free
survival; pts, patients; q3w, every third week; SD, stable disease; TTP, time to progression.
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respectively) and PFS (8.2, 9.0 and 10.1 months, respec-
tively), though seemingly to a lesser extent than when
combined with weekly paclitaxel [21]. OS was similar in
all treatment arms with median values of approximately
31 months.
The phase III trial (RIBBON-1) evaluated first-line
chemotherapy (anthracycline-based, taxane or capecita-
bine) with or without bevacizumab. Among 1,237
patients, the addition of bevacizumab to chemotherapy
resulted in an improvement in RR and PFS; however, no
significant OS advantage was seen [22]. Thus, although
these trials have demonstrated significant improvements
in RR and PFS, findings to date have not indicated
substantial benefit in terms of survival. Recently, a
meta-analysis of PFS and OS data from the three above-
mentioned trials (E2100, AVADO, RIBBON-1) including
2,447 patients has been published. Pooled results for
PFS showed an improved median PFS (6.7 to 9.2
months; P < 0.0001) for the bevacizumab-arm whereas
pooled results for OS showed no statistically significant
difference between the arms (26.4 versus 26.7 months).
However, 1-year survival was greater in the bevacizumab
arm (82 versus 77%; P = 0.003) [23].
Bevacizumab in combination with second-line stan-
dard chemotherapy (taxane, gemcitabine, capecitabine,
or vinorelbine) has been evaluated in a phase III trial
including 684 HER2-negative patients (RIBBON-2). The
addition of bevacizumab improved the median PFS (5.1
to 7.2 months; hazard ratio = 0.78; P = 0.0072). Sub-
g r o u pa n a l y s e ss h o w e dt h a tP F Sw a sc o n s i s t e n t l y
improved in the bevacizumab arms across all che-
motherapy cohorts [24,25].
Preclinical studies have suggested that oestrogen mod-
ulates VEGF-induced angiogenesis. It has been hypothe-
sised that adding bevacizumab to hormonal therapy
could reverse required endocrine resistance. MBC
patients who had progressed on hormonal therapy after
ap r e v i o u sr e s p o n s ew e r ei n c l u d e di nap h a s eI It r i a li n
which bevacizumab was added to the anti-hormonal
therapy. Results from this study (27 patients) showed no
responses but SD in 66% of the patients (duration not
reported) [26]. A phase II trial of bevacizumab plus
letrozole in 32 postmenopausal women with hormone-
receptor-positive advanced breast cancer (ABC) revealed
2 patients with PR and 13 with SD for 6 months or
more [27]. Preliminary results from a two arm noncom-
parative phase II study of bevacizumab combined with
anastrozole (25 patients) or fulvestrant (17 patients) as
first-line therapy in MBC reported promising results
w i t haP Rr a t eo f2 4 % ,aS Dr a t eo f5 7 % ,am e d i a nP F S
of 16.3 months for the anastrozole arm, and median
PFS not reached in the fulvestrant arm [28]. A similar
phase II study of bevacizumab plus fulvestrant in
Table 2 Phase III trials of bevacizumab in combination with chemotherapy in metastatic breast cancer
Reference Number of
patients
Therapy ORR (%) PFS (months)
Miller et al. [19] 232 B (15 mg/kg q3w) + capecitabine 20 (previous anthracycline and
taxane)
5 (TTP)
230 Capecitabine 9 (P = 0.001) 4
Miller et al. [20] (E2100) 368 (347 intent-to-
treat)
B (10 mg/kg q2w) + paclitaxel 37 (1st line) 12 (TTP)
354 (326 intent-to-
treat)
Paclitaxel 21 6 (P < 0.001)
Miles et al. [21] (AVADO) 248 B (7.5 mg/kg q3w) + docetaxel 55 (1st line) 9 (P = 0.045)
247 B (15 mg/kg q3w) + docetaxel 64 10 (P < 0.001)
241 Placebo + docetaxel 46 8
Robert et al. [22]
(RIBBON-1)
409 B (15mg/kg q3w) + capecitabine 35 (1st line) 10 (P = 0.0011)
206 Capecitabine 24 6
415 B (15 mg/kg q3w) + taxane or anthracycline-
based therapy
51 11 (P = 0.040)
207 Taxane or anthracycline-based therapy 38 8
Brufsky et al. [24,25]
(RIBBON-2)
684 B + chemotherapy (capecitabine, gemcitabine,
vinorelbine)
40 (2nd line) 7 (P = 0.0072)
Chemotherapy 30 5
B, bevacizumab; ORR, overall response rate; PFS, progression free survival; q2w, every second week; q3w, every third week; TTP, time to progression.
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inhibitor did not meet its statistical endpoint, as only
2 2 %( 1 1 %P R+1 1 %S D≥6 months) of the patients
achieved clinical benefit with a median PFS of 6.2
months [29].
Bevacizumab in early-stage breast cancer: preoperative
therapy
Results of phase II trials are given in Table 3 [30-38].
No phase III trials have been reported. A placebo con-
trolled double-blind randomised phase II trial investi-
gated neoadjuvant bevacizumab or placebo followed by
docetaxel, doxorubicin, and cyclophosphamide with or
without bevacizumab in patients with stage II or III
HER2-negative breast cancer. Of 37 patients, 95%
obtained objective responses, including 59% with CR.
The complete pathological response (pCR) rate has not
been reported. Congestive heart failure (CHF) grade 3
was reported in three patients and four patients had a
decline in left ventricular ejection fraction >15%; the
incidence was similar in the different treatment arms
[30]. A phase II study of bevacizumab in combination
with docetaxel and cyclophosphamide followed by dox-
orubicin has shown 38% pCR in the breast and 29% in
the breast and axilla among 36 patients. However, one
patient died of bilateral pulmonary embolism and one
developed CHF [31]. In contrast, no CR was reported in
21 patients with inflammatory or locally advanced breast
cancer after preoperative treatment with bevacizumab,
doxorubicin and docetaxel [34].
Preliminary results from a study evaluating bevacizu-
mab plus letrozole in the preoperative setting has
demonstrated an 18% pCR rate and a 74% overall
response rate (ORR) among 22 postmenopausal, hor-
mone-receptor-positive, HER2-negative patients [39].
Bevacizumab in early-stage breast cancer: adjuvant
therapy
It has been hypothesised that the most beneficial use of
antiangiogenic agents would be in the adjuvant setting.
However, concern exists about potential cardiac toxici-
ties, including CHF, particularly in patients receiving
bevacizumab in combination with anthracyclines. E2104
is a non-randomised trial designed to evaluate the safety
of incorporating bevacizumab in anthracycline-contain-
ing adjuvant therapy. Patients with lymph node-positive
breast cancer were sequentially assigned to adjuvant
chemotherapy consisting of dose dense doxorubicin and
cyclophosphamide followed by paclitaxel in combination
with bevacizumab (26 doses given every second week;
104 patients) or the same treatment but with sequential
treatment with bevacizumab (bevacizumab initiated con-
currently with paclitaxel; 122 patients) (Table 4) [40].
After a median follow-up of 15 and 11 months,
Table 3 Trials of bevacizumab in early-stage breast cancer: preoperative therapy
Reference Phase Number of patients Treatment Response rate (%)
Hurvitz
et al. [30]
II
(randomised)
37 of 90 planned (HER2-
negative)
A: TAC + B (7.5 mg/kg) All regimens: RR 95; CR
59; PR 35
B: TAC + placebo A: PR 58; CR 42
C: TAC + B (15 mg/kg) B + D: PR 27; CR 64
D: TAC + placebo (2:1:2:1, randomisation) D: PR 21; CR 71
Makhoul
et al. [31]
II 36 (11 HER2-negative) Bevacizumab + docetaxel + cyclophosphamide (4 cycles) ®
doxorubicin (4 cycles) ® bevacizumab (adjuvant, 9 cycles)
PR 31; CR 39; pCR breast
38; pCR breast + axilla 29
Greil et al.
[32]
II 18 (HER2-negative) Bevacizumab × 5* + (docetaxel + capecitabine) × 6* pCR 22
Balduzzi
et al. [33]
II 30 Epirubicin + cisplatin + fluorouracil × 4* ® bevacizumab +
paclitaxel × 3*
pCR 33; CR + PR 87
Wedam
et al. [34]
II 21 (81% HER2-negative) Bevacizumab × 1* ® bevacizumab + doxorubicin +
docetaxel × 6*
PR 67; CR 0
Lyons
et al. [35]
II 49 (number of patients
receiving bevacizumab not
reported)
Docetaxel + bevacizumab or docetaxel CR 14; PR 65
Raefsky
et al. [36]
II 25 Nab-paclitaxel + carboplatin × 6* + trastuzumab +
bevacizumab × 23*
pCR 26; PR 16
Locatelli
et al. [37]
II
(randomised)
23 (19 evaluable; locally
advanced)
B ® vinorelbine + capecitabine (9 pts) NR
B + vinorelbine + capecitabine (14 pts) NR
Torrisi
et al. [38]
II 37 (36 evaluable; estrogen
and/or progesterone positive)
Bevacizumab + capecitabine + vinorelbine + letrozole RR 86; pCR 0
Studies with ≥15 evaluable patients are included. B, bevacizumab, in combination with chemotherapy preoperatively plus adjuvant for 52 weeks; CR, complete
response; NR, not reported; pCR, pathological complete response; PR, partial response; pts, patients; RR, response rate; TAC, docetaxel, doxorubicin,
cyclophosphamide (six cycles preoperatively). *Times of treatment.
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and declines in left ventricular ejection fraction (LVEF)
<40% were recorded in four and one patient, respec-
tively. However, only 8 patients completed therapy in
the sequential arm, whereas 52 patients completed ther-
apy in the combination arm. No efficacy data have been
reported. Hart and colleagues [41] reported preliminary
safety data from a randomised phase II study designed
to test the feasibility of bevacizumab in combination
with three adjuvant docetaxel-containing regimens
(Table 4). Three early CHF cases were reported in
patients receiving anthracyclines. No cardiac events
were identified using the bevacizumab plus trastuzumab
combination. A phase II study of adjuvant bevacizumab
concomitant with trastuzumab and/or endocrine therapy
after neoadjuvant anthracycline-based therapy among 40
patients showed three recurrences within a median fol-
low-up of 8 months. No patient developed CHF [42].
Several studies are ongoing in the adjuvant setting.
E5103 is a phase III trial designed to succeed E2104.
The trial compares cyclophosphamide, paclitaxel, pegy-
lated liposomal doxorubicin plus placebo with the same
combination of chemotherapy plus bevacizumab with
the same combination of chemotherapy plus bevacizu-
mab followed by bevacizumab alone. The study is cur-
rently recruiting patients (planned enrolment 4,950
patients; NCT00433511). Another phase III trial (BEA-
TRICE) is designed to assess the benefit of adding beva-
cizumab to standard adjuvant chemotherapy
(anthracycline, taxane or combined anthracycline and
taxane based regimens). Approximately 3,000 patients
with triple-negative breast cancer will be randomised to
receive chemotherapy alone or in combination with bev-
acizumab for a total duration of 12 months
(NCT00528567). Finally, the phase III BETH trial evalu-
ates the addition of bevacizumab to adjuvant
chemotherapy and trastuzumab in patients with HER2-
positive breast cancer (estimated enrolment 3,500
patients; NCT00625898).
The tolerability of bevacizumab is generally acceptable,
and the drug can readily be administrated in combina-
tion with chemotherapeutic agents, which, in some cir-
cumstances, may be synergistic. Common adverse
events include asthenia, headache, hypertension, protei-
nuria, diarrhoea, nausea, vomiting, and stomatitis. Most
adverse events are mild to moderate and clinically man-
ageable. Serious but rare adverse events include gastro-
intestinal perforation, wound healing complications,
episodes of bleeding, and thrombosis [43].
VEGF trap
Novel agents targeting VEGF include the VEGF trap
aflibercept (developed by Regeneron, Tarrytown, NY, in
collaboration with Sanofi-Aventis, Bridgewater, NJ),
which is a fully human, soluble fusion protein. The pro-
tein construct consist of parts of the extracellular
domains of VEGFR1 and VEGFR2 fused to the Fc seg-
ment of human IgG1. Aflibercept binds and neutralises
all isoforms of VEGF and placental growth factor (PlGF)
and is the most potent VEGF blocker available, binding
VEGF with 100- to 1,000-fold higher affinity than other
reported VEGF antagonists [44]. A phase II study in 21
patients with MBC previously treated with an anthracy-
cline and/or a taxane reported a 5% PR rate and did not
meet efficacy goals [45].
Antibodies targeting integrins
The integrins are a family of at least 24 ab heterodi-
meric glycoproteins involved in cell matrix binding and
communication. The av integrins are expressed by
endothelial cells, particularly during angiogenesis, and
are implicated in signal transduction by VEGF, fibroblast
Table 4 Trials of bevacizumab in early-stage breast cancer: adjuvant therapy
Reference Phase Number of patients Treatment Clinical
CHF
LVEF
<40%
DFS
Miller et al. [40] II (two-arm non-
randomised)
104 B
1 + (ddAC ® paclitaxel) 2 4 NR
122 (HER2 status not
reported)
ddAC ® B + paclitaxel 2 1 NR
Hart et al. [41] IIb (randomised) 59 HER2-negative randomised: B
2 +A C
® T
1N R N R
61 B
2 + ACT 2 NR NR
39 HER2-positive: B
2 + TCH 0 NR NR
Mayer et al. [42] II 40 B
2 +/- trastuzumab +/- endocrine
therapy
00 N R
McArthur
et al. [112]
II 76 B
2 + ddAC × 4 ® nab-paclitaxel × 4 0 0 NR
AC, doxorubicin + cyclophosphamide; ACT, doxorubicin + cyclophosphamide + docetaxel; B
1, bevacizumab 10 mg/kg every second weeks × 26; B
2,
bevacizumab15 mg/kg every 3 weeks for a total of 52 weeks; CHF, congestive heart failure; ddAC, dose dense doxorubicin + cyclophosphamide; DFS, diseas-free
survival; LVEF, left vntricular ejection fraction; NR, not reported; T, docetaxel; TCH, docetaxel + carboplatin + trastuzumab.
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integrin inhibitors are under development - for example,
CNTO 95 (Centocor, Horsham, PA, and Janssen-Cilag
Pharmaceutical, SRL), a fully human antibody directed
against the av integrin receptor [46]. We did not iden-
tify breast cancer studies.
Anti-placental growth factor antibody
Recently, the effect of a neutralising murine anti-PlGF
antibody, TB-403 (Bioinvent International, Lund, Swe-
den, and ThromboGenics, Leuven, Belgium; Hoffmann-
La Roche Ltd, Basel, Switzerland), was reported. Unlike
VEGF, PlGF selectively binds VEGFR1 and its co-recep-
tors neuropilin-1 and -2. In vivo, the antibody inhibited
the growth and metastasis of various tumours, including
those resistant to VEGF inhibitors. Distinct from VEGF
inhibitors, TB-403 prevented infiltration of angiogenic
macrophages and severe tumour hypoxia, and thus did
not switch on the angiogenic rescue program responsi-
ble for resistance to VEGF. Potentially, the safety profile
of the drug is favourable as it did not affect healthy ves-
sels [47]. The drug is currently being investigated in a
phase I trial (NCT00702494).
Inhibitors of other receptors related to
angiogenesis: tyrosine kinase inhibitors
In parallel with the clinical development of bevacizu-
mab, multiple small molecule inhibitors of the VEGF
receptor tyrosine kinases have entered the clinic. A huge
number of small molecules are in pre-clinical and clini-
cal development (Table 5). Table 6 summarises the
results from trials utilising tyrosine kinase inhibitors,
many of which are still preliminary.
Sunitinib (Sutent®, SU11289; Pfizer, New York, NY,
USA) is a multitarget inhibitor with activity against
VEGF2, platelet-derived growth factor receptor (PDGFR)
b, stem cell factor receptor (c-Kit) and FLT3 tyrosine
kinase signaling pathways [48]. A phase II trial demon-
strated 11% PR and 5% SD among 64 patients with
refractory, late-stage MBC receiving sunitinib as mono-
therapy; median time to progression and OS were 10 and
38 weeks, respectively [49]. All phase I/II studies of suniti-
nib in combination with chemotherapy have shown activ-
ity and manageable toxicities [49-53]. However, a phase III
study of sunitinib plus paclitaxel versus bevacizumab plus
paclitaxel as first-line therapy in ABC (NCT00373256) has
been terminated prematurely as it would not have met its
primary goal (the primary endpoint being PFS). Further-
more, two phase III studies comparing docetaxel plus
sunitinib with docetaxel and capecitabine plus sunitinib
with capecitabine did not meet their primary endpoint of
prolongation of PFS despite a significantly increased ORR
(51% versus 39%) in the docetaxel study [54,55]. Finally, a
study comparing capecitabine with sunitinib in MBC has
been halted because of futility [56].
The most important treatment-related serious adverse
events have been pulmonary embolism, thrombocytope-
nia, tumour haemorrhage, febrile neutropenia, and
hypertension. The most common treatment-related
adverse events include fatigue, gastrointestinal disorders,
such as diarrhoea, nausea, stomatitis, dyspepsia and
vomiting, hand-foot syndrome, skin decolouration and
anorexia. A retrospective review of 75 patients with gas-
trointestinal tumours receiving sunitinib in phase I/II
trials showed 11% had CHF after repeated doses of suni-
tinib. The study underscores the importance of cardiac
monitoring [57].
Sorafenib (Nexavar®; Bayer AG Health Care, Lever-
kusen, Germany, and Onyx Pharmaceuticals, Emeryville,
CA, USA) is a multikinase inhibitor that targets Raf
kinase and the receptor tyrosine kinases VEGFR 1, 2,
and 3, PDGFRb, c-Kit and FLT3 [58]. A phase II study
of 54 pretreated MBC patients showed one with PR and
20 with SD (37%) [59]. The findings reflect those
obtained in renal cancer, in which SD has been the
main finding. A randomised phase IIb study (229 MBC
patients) comparing capecitabine plus sorafenib with
capecitabine plus placebo has shown significantly
increased PFS [60]. In addition, a randomised phase IIb
study comparing paclitaxel plus sorafenib with paclitaxel
plus placebo as first-line therapy in 237 MBC patients
demonstrated significant improvements in time to pro-
gression and ORR. However, the primary endpoint, PFS,
was not significantly increased [61] (Table 6). Like suni-
tinib, sorafenib is associated with fatigue, anorexia, diar-
rhoea, rash, and hand-foot syndrome.
Pazopanib (Armala®, GW786034; GlaxoSmithKline, Middle-
sex, UK) is a multitarget inhibitor with activity against VEGFR1,
2a n d3i na d d i t i o nt oP D G F R a/b and c-Kit [62]. A phase I
study of pazopanib alone in MBC revealed one with PR and 11
with SD among 19 patients [63].
Vatalanib (PTK787/ZK 222584; Novartis Institutes for
BioMedical Research Oncology, Basel, Switzerland) and
Table 5 Tyrosine kinase inhibitors targeting the
angiogenic pathway currently in clinical development in
breast cancer
Drug Target
Sunitinib VEGFR2, PDGFR-b, FLT3, c-Kit
Sorafenib VEGFR1, 2 and 3, PDGFR-b, FLT3, c-Kit, Raf
Pazopanib VEGFR1, 2 and 3, PDGFR-a/b, c-Kit
Vatalanib VEGF1, 2 and 3, PDGFR, c-Kit, c-Fos
Cediranib VEFGR1, 2 and 3, PDGFR, c-Kit
Vandetanib VEGFR2, EGFR, RETS
AMG 706 VEGFR1, 2 and 3, PDGFR-b, c-kit
Axitinib VEGFR1, 2 and 3, PDGFR, c-Kit
EGFR, epidermal growth factor receptor; PDGFR, platelet-derived growth factor
receptor; VEGFR, vascular endothelial growth factor receptor.
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ceuticals, London, UK) are pan-VEGF, PDGFR, and
c-Kit receptor tyrosine kinase inhibitors [64]. No results
have yet been published with regard to breast cancer.
Vandetanib (ZD6474; Zactima®; AstraZeneca, London,
UK) is a VEGFR2 inhibitor that also has activity against
epidermal growth factor and RETS receptor tyrosine
kinases [65]. The compound exhibited little activity in
MBC [66]. A randomised phase II study of docetaxel
plus vandetanib or placebo as second-line therapy in 64
patients with ABC showed no difference between the
two arms [67].
The nicotinamide motesanib diphosphate (AMG 706;
Amgen Inc., Thousand Oaks, CA, USA) is a multikinase
inhibitor of VEGFR1, 2 and 3, PDGFR and c-Kit [68]. A
phase Ib study of motesanib diphosphate in combination
with paclitaxel or docetaxel in locally advanced breast
cancer is ongoing. Preliminary results have shown that
the combinations are tolerable [69].
Axitinib (AG-013736) is a tyrosine kinase inhibitor
with activity against VEGFR1, 2 and 3, PDGFR and
c-Kit [70]. This agent in combination with docetaxel has
been compared to docetaxel in a randomised phase II
trial. The addition of axitinib significantly increased
Table 6 Trials of tyrosine kinase inhibitors targeting the angiogenic pathway in metastatic breast cancer
Reference Phase Number of
patients
Treatment Response (%) PFS (months)
Burstein et al. [49] II 64 Sunitinib PR 2; SD ≥6
months 8
2.5 (TTP)
Lyandres et al. [50] I 15 Sunitinib + cyclophosphamide
+ methotrexate
PR 7; SD >6
months 7
NR
Gianni et al. [51] II 13 Sunitinib + docetaxel PR 61; SD 23 NR
Kozloff et al. [52] I 20 Sunitinib + paclitaxel CR 10; PR 15 NR
Wildiers et al. [53] II
(randomised)
36 Taxane® sunitinib NR 3.4
19 Taxane ® no treatment NR 3.1
NCT00373256 III NR Paclitaxel + sunitinib Paclitaxel
+ bevacizumab
Did not meet primary end point (increased PFS)
Bergh et al. [54] III 296 Docetaxel + sunitinib 51 8.6; OS 24.8
297 Docetaxel + placebo 39 8.3; OS 25.5
Crown et al. [55] III 221 Capecitabine + sunitinib 19 5.5; OS 16.4
221 Capecitabine 16 5.9; OS 16.5
Barrios et al. [56] III 244 Sunitinib 11 2.8; OS 15.3
238 Capecitabine 16 4.2; OS 24.6
Bianchi et al. [59] II 54 Sorafenib PR 1; SD ≥6
months 37
NR
Baselga et al. [60] II
(randomised)
114 Capecitabine + sorafenib NR PFS increased (P = 0.0006 versus
Capecitabine + placebo)
115 Capecitabine + placebo
Gradishar et al. [61] II
(randomised)
119 Paclitaxel + sorafenib 67 6.9; TTP 8.1
118 Paclitaxel + placebo 54 5.6 (P = 0.0857); TTP 5.6 (P = 0.0171)
Isaacs et al. [113] I/II 35 Anastrozole + sorafenib CBR 20 (PR + SD ≥6
months)
NR
Taylor et al. [63] I 21 Pazopanib PR 5; SD ≥6
months 21
3.7 (TTP)
Miller et al. [66] II 46 Vandetanib SD ≥6 months 2 NR
Boér et al. [67] II
(randomised)
35 Docetaxel + vandetanib NR 9
29 Docetaxel + placebo NR 6
de Boer et al. [69] I 13 (9
evaluable)
Motesanib diphosphate +
taxane
PR 22; SD ≥6
months 11
NR
Rugo et al. [71] II
(randomised)
168 Docetaxel + axitinib 40 8.2 (TTP)
Docetaxel 23 7.0 (P = 0.052)
CBR, clinical benefit rate; CR, complete response; NR, not reported; ORR, overall response; OS, overall survival; PFS, progression free survival; PR, partial response;
pts, patients; SD, stable disease; TTP, time to progression.
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sion [71].
In general, these above-mentioned trials have shown
some activity of tyrosine kinase inhibitors in MBC,
although results have been heterogeneous. Thus, phase
II randomised trials including sorafenib or axtinib have
shown increased PFS [60,71]. On the other hand, other
trials have been negative [66,67] and accumulated data
from recent trials did not support the use of sunitinib in
the treatment of MBC [53-56]. The reason for the lack
of effect is probably multifactorial. One explanation
could be insufficient dose intensity due to toxicity.
Furthermore, the patient populations in many of the
studies have been heterogeneous and heavily pretreated.
For other reasons see the Discussion section. It is possi-
ble, however, that drugs like, for example, sunitinib are
active within a small, specific subgroup of patients.
g-Secretase inhibitors
The Notch-Delta-like signaling pathway plays an impor-
tant oncogenic role in breast tumour development in
animal models and is probably also significant in human
breast tumours. Central to Notch activation is g-secre-
tase, which cleaves Notch, allowing its translocation to
the nucleus, where it activates target genes. Thus,
inhibition of g-secretase function would prevent Notch
signal transduction [72]. The g-secretase inhibitor MK-
0752 (Merck and Co., Inc., Whitehouse Station, NJ,
USA) is currently being evaluated in a phase I/II study.
Inhibition of angiopoietin
AMG 386 (Amgen Inc., Thousand Oaks, CA, USA) is a
fusion protein containing a synthetic peptide exhibiting
high affinity for angiopoietins fused to the constant
region of human IgG1 [73]. By neutralising angiopoietin
1 and 2, the drug inhibits Tie2-dependent stimulation of
endothelial cells. Recent data implicate angiopoietin 2 as
an important mediator of the angiogenic process. A
phase II placebo-controlled trial in HER2-negative ABC
comparing the efficacy of paclitaxel plus AMG 386 ver-
sus paclitaxel plus bevacizumab versus paclitaxel in
combination with both drugs has been initiated
(NCT00511459).
mTOR inhibitors
mTOR is a serine-threonine protein kinase downstream
of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway.
This pathway regulates several cellular functions that
are critical to tumourigenesis. Evidence suggests that
aberrant activation of this pathway plays a major role in
breast cancer cell proliferation and in several anti-cancer
drug resistance mechanisms. Additionally, mTOR activa-
tion increases translation of hypoxia-inducible factor 1a
and thereby VEGF [74].
Currently, the mTOR inhibitors temsirolimus (CCI-
779 (cell-cycle inhibitor)-779; Torisel®; Wyeth Pharma-
ceuticals, Inc., Madison, NJ, USA) [75], everolimus
(RAD001, Afinitor®; Novartis Institutes for BioMedical
Research Oncology, Basel, Switzerland) [76], and rida-
forolimus, formerly known as deforolimus (AP23573;
ARIAD Pharmaceuticals Inc., Cambridge, MA, USA;
MK-8669; Merck and Co., Inc., Whitehouse Station, NJ,
USA) [77] are studied in MBC. A phase II randomised
study of two dose levels of temsirolimus in 109 patients
with previously treated ABC reported an ORR of 9% (10
with PR) and a CBR of 14% (SD ≥6 months) [78]. Gen-
erally, results have been rather disappointing with a
lower-than expected RR (Table 6) [74,79]. Thus, mono-
therapy with mTOR inhibitors has limited activity in
breast cancer (and other cancer types). A potential
explanation could be related to a collateral effect of
mTOR blockade. Thus, mTOR inhibition blocks the
natural negative feed-back on the insulin-like growth
factor-1 receptor signaling that inhibits PI3K activation.
The result is an increase in PI3K and Akt activation,
which could potentially counteract the inhibition of
mTOR [80]. The adverse side effects of mTOR inhibitor
monotherapy are fatigue, skin rash, stomatitis, increased
triglycerides, increased glucose and decreased phosphor.
However, these side effects are generally mild. Table 7
summarises trials investigating mTOR inhibitors in
MBC.
A phase I trial assessing the combination of everoli-
mus and docetaxel has been terminated as the pharma-
cokinetic analysis showed variable and unpredictable
changes in docetaxel clearance, making the combination
unfeasible. No objective response was observed in 15
patients [81]. On the other hand, a phase Ib study of
everolimus in combination with cisplatin and paclitaxel
was well tolerated with significant antitumour activity
(RR 23%) [82].
Based on the crosstalk between the oestrogen receptor
and the PI3K/Akt/mTOR pathway, several clinical trials
have explored the combination of an mTOR inhibitor
with endocrine therapy. Early data from a randomised
three-arm phase II study of temsirolimus in combina-
tion with letrozole in 92 postmenopausal women with
ABC has shown clinical activity, with prolonged PFS in
the combination arms compared with the letrozole
mono-therapy arm [83]. A large phase III study tested
temsirolimus combined with letrozole against letrozole
alone in 1,112 postmenopausal women with ABC [84].
The study was terminated prematurely because more
grade 3 toxicities were reported with the combination
arm. In addition, no improvements in RR or PFS were
seen with the combination compared to letrozole alone
(RR 27% in both treatment arms; PFS 8.8 and 8.9
months, respectively).
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mTOR inhibitors in early-stage breast cancer. A phase
II trial of everolimus monotherapy for 14 days prior to
surgery in 30 postmenopausal women with early breast
cancer has shown significantly reduced tumour cell pro-
liferation [85]. Furthermore, Baselga and colleagues [86]
presented the results of the combination of everolimus
plus letrozole in a randomised phase II neoadjuvant trial
of 270 oestrogen receptor-positive breast cancer
patients. The RR with everolimus plus letrozole was
superior to that of placebo plus letrozole (68% versus
59%).
Antiangiogenic therapies in combination with
other targeting therapies
Angiogenesis is a complex process composed of multiple
signaling pathways. Many of these pathways are redun-
dant, with several ligand-receptor combinations resulting
in the same eventual downstream events. It is unlikely
that tumours are entirely dependent on only one abnor-
mally activated signaling pathway; consequently, treat-
ment with an agent that interferes with a single target
may be insufficient. Simultaneous blockade of multiple
pathways has become an attractive therapeutic strategy
[87]. Table 9 summarises trials using combination tar-
geting therapies.
Bevacizumab plus trastuzumab
The HER2 gene is overexpressed in 18 to 25% of all pri-
mary breast cancers. Trastuzumab (Herceptin®; Genen-
tech Inc., San Francisco, CA, and Hoffmann-La Roche
Ltd., Basel, Switzerland) is a recombinant, monoclonal
humanised murine antibody directed against the extra-
cellular portion of the HER2 protein. The precise
mechanism of its anti-tumour action has not been fully
elucidated. Several molecular and cellular effects have
been observed, including inhibition of HER2 extracellu-
lar proteolysis, disruption of downstream cellular path-
ways, cell-cycle arrest, inhibition of DNA repair,
suppression of angiogenesis, and induction of antibody-
dependent cell-mediated cytotoxicity. Measurements of
HER2 and VEGF in primary breast tumour tissue have
demonstrated a positive association between HER2 and
VEGF expression [88]. Therefore, the combination of
inhibitors against HER2 and VEGF might be a rational
treatment strategy for patients with HER2-positive
breast cancer. Preliminary results from a phase II trial
(50 patients) of trastuzumab plus bevacizumab as first-
line treatment in HER2-positive MBC have demon-
strated a 48% RR, including 2 patients with CR [89].
However, 19 cardiac adverse events were reported, one
of which was symptomatic (grade 4). Thus, the combi-
nation requires stringent cardiac surveillance.
Table 7 Trials of mTOR inhibitors in metastatic breast cancer
Reference Phase Number of patients Treatment Response (%) PFS (months)
mTOR inhibitor monotherapy
Chan et al. [78] II (randomised) 109 Temsirolimus (two dose levels) ORR 9 NR
Ellard et al. [79] II (randomised) 49 (33: daily schedule) Everolimus (two different schedules) ORR 12 (daily schedule) NR
ORR 0 (weekly schedule) NR NR
mTOR inhibitor plus chemotherapy
Moulder et al. [81]* I 15 Everolimus + docetaxel RR 0 NR
Mayer et al. [82] Ib 16 Everolimus + cisplatin + paclitaxel RR 23 NR
mTOR inhibitor plus endocrine therapy
Carpenter et al. [83] II (randomised) 33: daily Temsirolimus (two schedules) + letrozole PR 27 Not reached
30: intermittent CR 3, PR 27 Not reached
29 Letrozole CR 7 + PR 34 9.2
Chow et al. [84]* III 556 Temsirolimus + letrozole ORR 27 8.8
556 Letrozole ORR 27 8.9
*Study terminated due to toxicity. CR, complete response; mTOR, mammalian target of rapamycin; NR, not reported; ORR, overall response rate; PFS, progression
free survival; PR, partial response; RR, response rate.
Table 8 Trials of mTOR inhibitors in early-stage breast cancer: preoperative therapy
Reference Phase Number of patients Treatment Response
Macaskill et al. [85] II 30 Everolimus (14 days prior to surgery) Reduced cell proliferation
Baselga et al. [86] II (randomised) 270 Everolimus + letrozole RR 68%
Letrozole 59%
mTOR, mammalian target of rapamycin; RR, response rate.
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Erlotinib (Tarceva®; Genentech Inc., San Francisco, CA,
USA, and Hoffmann-La Roche Ltd., Basel, Switzerland)
is an inhibitor of the HER1 (epidermal growth factor
receptor) tyrosine kinase. Results from a phase II trial of
the combination of bevacizumab and erlotinib in 38
MBC patients has been disappointing (1 with PR and 4
with SD >6 months) [90].
Bevacizumab plus lapatinib
Lapatinib (Tyverb®, GW572016; GlaxoSmithKline, Mid-
dle-sex, UK) is a dual tyrosine kinase inhibitor of HER1
and HER2. Like trastuzumab, the compound may have
angiogenic downstream effects. A phase II study of bev-
acizumab plus lapatinib in 52 (27 evaluable) patients
with HER2- positive MBC showed an ORR of 13% and
a CBR of 34%. The combination was generally well tol-
erated [91].
Sunitinib plus trastuzumab
Preliminary results from an ongoing phase II trial in
patients with HER2-positive ABC have shown an ORR
of 35% and a CBR of 48% among 52 patients receiving
sunitinib combined with trastuzumab [92]. Further-
more, the combination of sunitinib, trastuzumab, and
docetaxel as first-line therapy in 25 women with
HER2-positive MBC showed one with CR and 14 with
PR [93].
Pazopanib plus lapatinib
Recently, results from a randomised, phase II study
investigating lapatinib alone or in combination with
pazopanib as first-line therapy in HER2-positive MBC
patients have been presented. A pre-specified interim
analysis of 62 patients demonstrated a RR of 44% after
treatment with the combination regimen compared with
30% after treatment with lapatinib alone [94]. The study
underscores that the combination of VEGF- and HER2-
targeted therapies could result in substantial clinical
benefit.
Everolimus/ridaforolimus plus trastuzumab
A phase I trial including 22 (17 evaluable) patients with
trastuzumab-resistant MBC treated with paclitaxel plus
everolimus plus trastuzumab resulted in 5 with PR and
2 with SD >16 weeks [95]. In addition, a phase II trial
including 22 (14 evaluable) similar patients treated with
a combination of ridaforolimus and trastuzumab has
shown 2 with PR [96]. Both combinations were well
tolerated.
Everolimus plus erlotinib
A phase Ib study of the combination of everolimus plus
erlotinib in 14 patients with MBC showed that the regi-
men was well tolerated. However, the authors concluded
that the combination was clinically ineffective and did
not warrant further testing in breast cancer [97].
Combinations of antiangiogenic therapies
Bevacizumab plus sunitinib
A randomised phase II study of paclitaxel plus bevacizu-
mab versus paclitaxel plus bevacizumab plus sunitinib as
first-line therapy in HER2-negative MBC reported a
high rate of dose modifications and/or discontinuations
of sunitinib due to toxicity. The authors concluded that
the combination was not feasible and the study was
closed [98].
A phase I study of bevacizumab in combination with
sunitinib, sorafenib, erlotinib plus cetuximab, or trastu-
zumab plus lapatinib has shown that all combinations
were tolerable and prelimina r ye v i d e n c eo fa n t i t u m o u r
activity was demonstrated (the bevacizumab plus suniti-
nib combination was discontinued due to toxicity data
from other studies) [99].
Table 9 Antiangiogenic therapy in combination with other targeting therapies
Combination
Targeting angiogenesis Targeting HER1 or 2
Reference Chemotherapy Monoclonal
antibody
Tyrosine kinase
inhibitor
mTOR
inhibitor
Monoclonal
antibody
Tyrosine kinase
inhibitor
Hurvitz et al. [89]
Dickler et al. [90] Bevacizumab Erlotinib
Dickler et al. [91] Bevacizumab Lapatinib
Blay et al. [92] Sunitinib Trastuzumab
Dirix et al. [93] Docetaxel Sunitinib Trastuzumab
Slamon et al. [94] Pazopanib Lapatinib
O’Regan et al. [95] Paclitaxel Everolimus Trastuzumab
Yardley et al. [96] Ridaforolimus Trastuzumab
Mayer et al. [97] Everolimus Erlotinib
HER, human epidermal growth factor receptor; mTOR, mammalian target of rapamycin.
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Antiangiogenic drugs work essentially in combination
with chemotherapy. One possible mechanism for this
phenomenon is normalisation of the tumour vascula-
ture, thereby increasing the concentration of drug in the
tumour [100].
Despite the promising activity of antiangiogenic drugs
in preclinical tumour models, targeting VEGF signaling
appears to be insufficient to permanently inhibit tumour
angiogenesis. The reasons for this are likely to be multi-
ple and complex. Some critical issues that may be, at
least in part, responsible for the failures have been sug-
gested. Primarily, the choice of the appropriate molecu-
lar target is essential to the ultimate success of a given
therapeutic intervention. Thus, patient selection strate-
gies are of paramount importance. The challenge
remains to identify markers predicting the effects of
antiangiogenic treatment (see ‘Biomarkers of angiogen-
esis and evaluation of response’ below). In contrast to
renal cell cancer, there is no documented constitutive
activation of the VEGF pathway in breast cancer. How-
ever, it is possible that drugs targeting this pathway are
very effective within a small, specific subgroup of
patients.
Most current antiangiogenic therapies are based on
inhibition of VEGF functions. However, tumours also
produce multiple non-VEGF angiogenic factors, making
angiogenesis a complex process composed of multiple
signaling pathways, many of which are redundant. Thus,
a switch on the angiogenic rescue program is possibly
responsible for resistance to VEGF. Preclinical studies
have identified four potential mechanisms of resistance:
upregulation of basic fibroblast growth factor; over-
expression of matrix metalloproteinase-9; increased level
of stromal-cell-derived factor 1a; and hypoxia-inducible
factor 1a-induced recruitment of bone-marrow-derived
CD45+ myeloid cells [101,102].
Clonal evolution and tumour adaptation may also
result in a tumour that is more tolerant to hypoxia and
subsequently less dependent on neovascularization.
Finally, substantial inherited variability within VEGF and
its receptor (VEGFR2) has been demonstrated, making
it plausible that a certain subgroup of patients with a
specific genotype may derive sustained benefit from
VEGF inhibition [103].
Issues regarding the future of antiangiogenic therapy
The E2100 trial represents the first successful proof-of-
concept trial for antiangiogenic therapy in breast cancer
[20]. However, in spite of improvements in RR and PFS,
all randomised studies of antiangiogenic therapy in
breast cancer have so far failed to demonstrate an
impact on OS. This may be the reason why there is not
yet general agreement on the use of bevacizumab in
MBC.
Numerous challenges remain. Several tyrosine kinase
inhibitors and other agents targeting the angiogenic
pathway are in development. Their role has to be estab-
lished. Furthermore, we do not know which combina-
tions of antiangiogenic agents and standard agents
(chemotherapy, hormonal, or biological) will prove most
effective. The timing of angiogenesis therapy is also a
challenge. This includes the optimal sequence of such
therapies. Furthermore, questions about the duration of
therapy and even dosages are unanswered. For example,
therapy in patients with response or stable disease
might be beneficial but difficult to justify without defi-
nite survival advantages.
There is increasing evidence that targeting of tumour
epithelium and pericytes by combined VEGF and
PDGFR blockade may facilitate the metastatic process.
Thus, recent articles report how malignant tumours
escape from antiangiogenic therapy by metastatic disse-
mination [104]. These findings might have important
implications for the potential use of antiangiogenic ther-
apy in the adjuvant setting. On the other hand, no clini-
cal evidence for increases in the malignant potential of
tumours was demonstrated in patients with MBC trea-
ted with bevacizumab and docetaxel in the phase III
AVADO study [21,105].
Biomarkers of angiogenesis and evaluation of response
Many biomarkers of angiogenesis have been proposed as
predictors for response to antiangiogenetic therapy, but
none has yet been identified. Pretreatment plasma levels
of VEGF have been evaluated in a range of studies. Gen-
erally, elevated levels are indicative of poor prognosis,
but do not predict response to antiangiogenic therapy,
including bevacizumab. Considerable research has been
conducted to test the possibility that single-nucleotide
polymorphisms in the germ-line involving angiogenesis-
related genes influence the natural history of the disease
and its response to treatment. Recently, an association
between the VEGF genotype and median OS and severe
hypertension has been demonstrated in MBC patients
receiving bevacizumab and paclitaxel (E2100) [103].
Other approaches include measuring microvessel density
or circulating endothelial cells. Recently, the topic has
been reviewed by Jain and colleagues [106] and Muru-
kesh and colleagues [107]. Molecular markers to moni-
tor the effect of mTOR inhibitors have been identified
in preclinical studies showing tumour growth inhibition
to correlate with a decrease of pS6K1 and p4EBP1 [68].
However, findings from clinical studies are still too lim-
ited to base selection of patients and dose selection on
these biomarkers.
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ical efficacy. Although objective change in tumour size
remains an important assessment criterion for the treat-
ment of solid tumours, tumour regression rate or RR
might be more relevant as surrogate markers for cyto-
toxic chemotherapy than for targeted biological agents,
which are primarily cytostatic. Thus, assessing only
lesion size has demonstrated an inherent limitation
when evaluating antiangiogenic drugs. In trials including
these agents, disease control or time to progression may
be more relevant than conventional response evaluation
(PR and CR). Functional imaging - for example, dynamic
contrast-enhanced magnetic resonance imaging/compu-
ter tomography, positron-emission tomography or con-
trast-enhanced ultrasound - has been included in several
studies. The topics have been comprehensively reviewed
by Sessa and colleagues [108] and Marcus and collea-
gues [109].
Cost
Monoclonal antibodies and tyrosine kinase inhibitors are
relatively expensive in comparison with other cancer
therapies. Economic evaluations are needed to clarify
whether these expensive treatment options are cost
effective. In the metastatic setting, where the goal is to
improve quality of life and/or delay the time to disease
progression, it is not clear whether health care systems
can (or should) carry these expenses [110]. Under any
circumstances, resource planning will be needed in
order to offer these treatments to all suitable patients.
Identifying subgroups of patients who will benefit from
treatment and avoid administration to patients who are
unlikely to respond significantly improve the cost/bene-
fit ratio [111].
Conclusion
Development of drugs targeting angiogenesis is in pro-
gress and so far there is support for the use of the anti-
body bevacizumab in combination with taxanes
(paclitaxel) as first-line therapy in HER2-negative MBC.
Targeted therapy is an area of research and possibly
represents an important step in the treatment of MBC.
Results of ongoing trials and maturation of the pub-
lished trials will hopefully lead to more precise knowl-
edge, and thus more cost-effective use of recent
developments. Identification of predictive biomarkers
and improvement of our understanding of molecular
mechanisms is crucial.
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